WASHINGTON – Far from being doomed after the failure SYMPLICITY HTN-3, renal denervation for refractory hypertension will continue to be explored. But it can’t go very far without finding a way to...
Neither perioperative aspirin therapy nor perioperative clonidine prevented death or MI in patients undergoing noncardiac surgery who were at risk for major vascular complications, according to data...
WASHINGTON – Renal denervation’s not so simple after all.
Highly anticipated data from the large, sham-controlled renal-artery catheter denervation trial, SYMPLICITY HTN-3, gave its investigators...
WASHINGTON – A first in transcatheter aortic valve replacement trials, the CoreValve prosthesis was superior to surgical valve replacement in patients with severe aortic stenosis at increased...
WASHINGTON – What can explain the failure of SYMPLICITY HTN-3? After clinical success in reducing blood pressure by 20-30 mm HG in patients with resistant hypertension, the renal denervation...
WASHINGTON – Transcatheter aortic valve replacement with the CoreValve device showed significantly higher 1-year survival than did surgical replacement, in a randomized trial of patients with severe...
WASHINGTON – Transcatheter aortic valve replacement with the CoreValve device showed significantly higher 1-year survival than did surgical replacement, in a randomized trial of patients with severe...
SNOWMASS, COLO. – Transcatheter aortic valve replacement in nonsurgical candidates with severe symptomatic aortic stenosis carries a hefty price tag of $116,500 per quality-adjusted life-year gained...
SNOWMASS, COLO. – Transcatheter aortic valve replacement in nonsurgical candidates with severe symptomatic aortic stenosis carries a hefty price tag of $116,500 per quality-adjusted life-year gained...